Stock of epidemic prevention concept:
1, spotlight technology: the net profit in 2020 is 489 million, up 1 128.82% year-on-year.
On February 2, 2020, KLOC-0, the company said on the interactive platform that the local CDC was a customer of Yoshida Instruments, a subsidiary of the company. The main products are atomic fluorescence photometer and flow injection analyzer, and some products have been put into anti-epidemic and epidemic prevention in Hubei and Yunnan.
2. Panlong Pharmaceutical: The annual report of 2020 shows that Panlong Pharmaceutical achieved a net profit of 79120,000 yuan, a year-on-year increase of 10.22%.
The first batch of 75% single-sided ethanol disinfectant products produced by the company have been put into the epidemic prevention line. The company will speed up the production of 75% single-sided ethanol disinfectant and do its best to meet the market demand for epidemic prevention and control materials.
3. Health in the United States: The 2020 annual report shows that health in the United States achieved a net profit of 554 million yuan.
The company has put forward two schemes for anti-epidemic screening, among which "novel coronavirus nucleic acid detection scheme" focuses on virus nucleic acid detection and "Deep lung examination scheme" focuses on low-dose spiral CT image examination.
4. Mindray Medical: The net profit in 2020 was 6.658 billion, up 42.24% year-on-year.
In March, 2000, the company received purchasing demand from overseas, including Asia-Pacific, Europe, Middle East and other regions, to cope with the epidemic. Recently, due to the rapid warming of the epidemic in Italy, the Italian government urgently purchased nearly 10,000 epidemic prevention equipment from Mindray, including monitors and ventilators.
5. Zhongsheng Pharmaceutical: The company's net profit in 2020 was-427 million yuan, a year-on-year increase of -234.27%.
In February, 2000, the chloroquine phosphate tablets produced by the company will be kept by the Material Support Group of the epidemic prevention and control headquarters in novel coronavirus, Guangdong Province, and the company will join forces with all parties to mass-produce chloroquine phosphate tablets to help win the "anti-epidemic" war.
6. Fosun Pharma: The net profit in 2020 was 3.663 billion, up 65,438+00.27% year-on-year.